- 大部份公司都有淡旺季, 所以通常是看年增率
- 如果是成長期(在炒新的成長動能)的公司或景氣從谷底翻揚, 就可以觀察月增率
- 漲很多的股票要留意營收年增率或月增率大幅減少, 又或者是合約負債已經開始減少
- 留意短期平均營收向上或向下穿越長期平均營收
- 觀察累計營收年增率的累計增加或虧損收斂
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026/4 | 0.94 | -6.07 | -10.29 | 3.56 | -41.13 | 2.63 | N/A | - | ||
| 2026/3 | 1.0 | 48.37 | -67.9 | 2.62 | -47.63 | 2.62 | 2.49 | . | ||
| 2026/2 | 0.68 | -27.43 | -24.0 | 1.61 | -13.58 | 2.56 | 2.55 | - | ||
| 2026/1 | 0.93 | -1.27 | -4.04 | 0.93 | -4.04 | 2.78 | 2.35 | - | ||
| 2025/12 | 0.95 | 4.99 | -11.05 | 15.83 | 15.28 | 3.27 | 1.78 | - | ||
| 2025/11 | 0.9 | -36.66 | -17.2 | 14.88 | 17.49 | 4.03 | 1.44 | - | ||
| 2025/10 | 1.42 | -16.66 | 22.88 | 13.98 | 20.75 | 4.23 | 1.37 | - | ||
| 2025/9 | 1.71 | 54.09 | -14.38 | 12.56 | 20.51 | 3.97 | 1.67 | - | ||
| 2025/8 | 1.11 | -4.07 | -2.8 | 10.85 | 28.76 | 3.62 | 1.84 | - | ||
| 2025/7 | 1.15 | -14.85 | -6.59 | 9.75 | 33.69 | 3.7 | 1.79 | . | ||
| 2025/6 | 1.36 | 13.77 | 21.83 | 8.59 | 41.91 | 3.6 | 1.93 | - | ||
| 2025/5 | 1.19 | 13.21 | -16.18 | 7.24 | 46.43 | 5.37 | 1.29 | , | ||
| 2025/4 | 1.05 | -66.39 | 4.39 | 6.05 | 71.71 | 5.07 | 1.37 | . | ||
| 2025/3 | 3.13 | 251.3 | 202.95 | 4.99 | 98.7 | 4.99 | 1.35 | 完成資產交易及技術授權所致 | ||
| 2025/2 | 0.89 | -8.37 | 27.9 | 1.86 | 25.92 | 2.93 | 2.31 | - | ||
| 2025/1 | 0.97 | -8.49 | 24.15 | 0.97 | 24.15 | 3.12 | 2.16 | - | ||
| 2024/12 | 1.06 | -2.25 | 21.73 | 13.73 | 18.57 | 3.31 | 1.95 | - | ||
| 2024/11 | 1.09 | -5.99 | -14.65 | 12.66 | 18.31 | 4.24 | 1.52 | - | ||
| 2024/10 | 1.16 | -41.94 | -26.01 | 11.58 | 22.76 | 4.29 | 1.5 | . | ||
| 2024/9 | 1.99 | 74.95 | 10.77 | 10.42 | 32.46 | 4.37 | 1.42 | - | ||
| 2024/8 | 1.14 | -7.82 | -31.56 | 8.43 | 38.88 | 3.49 | 1.78 | - | ||
| 2024/7 | 1.24 | 11.06 | 74.86 | 7.29 | 65.49 | 3.77 | 1.64 | . | ||
| 2024/6 | 1.11 | -21.72 | 41.86 | 6.05 | 63.7 | 3.54 | 1.8 | . | ||
| 2024/5 | 1.42 | 41.0 | 93.24 | 4.94 | 69.58 | 3.46 | 1.85 | . | ||
| 2024/4 | 1.01 | -2.46 | 89.36 | 3.52 | 61.6 | 2.74 | 2.33 | . | ||
| 2024/3 | 1.03 | 48.32 | 92.92 | 2.51 | 52.63 | 2.51 | N/A | . | ||
| 2024/2 | 0.7 | -11.07 | 35.36 | 1.48 | 33.2 | 2.34 | N/A | . | ||
| 2024/1 | 0.78 | -9.32 | 31.34 | 0.78 | 31.34 | 2.92 | N/A | - | ||
| 2023/12 | 0.86 | -32.18 | 32.24 | 11.57 | 9.55 | 3.7 | N/A | . | ||
| 2023/11 | 1.27 | -18.5 | 76.26 | 10.7 | 8.05 | 4.64 | N/A | . | ||
| 2023/10 | 1.56 | -13.07 | 136.48 | 9.43 | 2.68 | 5.03 | N/A | . | ||
| 2023/9 | 1.8 | 8.08 | 166.77 | 7.87 | -7.69 | 4.17 | N/A | . | ||
| 2023/8 | 1.66 | 135.5 | 232.42 | 6.07 | -22.67 | 3.15 | N/A | . | ||
| 2023/7 | 0.71 | -9.89 | 30.75 | 4.4 | -40.05 | 2.23 | N/A | . | ||
| 2023/6 | 0.78 | 6.62 | -2.43 | 3.7 | -45.67 | 2.05 | N/A | . | ||
| 2023/5 | 0.74 | 38.18 | 19.39 | 2.91 | -51.46 | 1.8 | N/A | . | ||
| 2023/4 | 0.53 | -0.63 | -1.59 | 2.18 | -59.56 | 1.58 | N/A | . | ||
| 2023/3 | 0.54 | 4.06 | -66.85 | 1.65 | -66.03 | 1.65 | N/A | . | ||
| 2023/2 | 0.51 | -13.7 | 9.94 | 1.11 | -65.61 | 1.76 | N/A | . | ||
| 2023/1 | 0.6 | -8.7 | -78.41 | 0.6 | -78.41 | 1.97 | N/A | . | ||
| 2022/12 | 0.65 | -9.61 | -81.29 | 10.56 | -73.07 | 2.04 | N/A | . | ||
| 2022/11 | 0.72 | 9.33 | -93.96 | 9.91 | -72.27 | 2.06 | N/A | . | ||
| 2022/10 | 0.66 | -1.93 | -89.49 | 9.18 | -61.33 | 1.84 | N/A | . | ||
| 2022/9 | 0.67 | 34.68 | -88.47 | 8.52 | -51.19 | 1.71 | N/A | . | ||
| 2022/8 | 0.5 | -7.36 | -93.47 | 7.85 | -32.42 | 1.84 | N/A | . | ||
| 2022/7 | 0.54 | -32.76 | 61.05 | 7.35 | 86.45 | 1.96 | N/A | . | ||
| 2022/6 | 0.8 | 30.48 | 48.86 | 6.81 | 88.82 | 1.96 | N/A | . | ||
| 2022/5 | 0.62 | 13.88 | 8.59 | 6.0 | 95.85 | 2.77 | N/A | . | ||
| 2022/4 | 0.54 | -66.53 | -15.72 | 5.39 | 115.66 | 2.62 | N/A | . | ||
| 2022/3 | 1.62 | 245.24 | 119.88 | 4.85 | 161.08 | 4.85 | N/A | 新冠肺炎疫苗自110年8月開始銷售 | ||
| 2022/2 | 0.47 | -83.06 | -12.78 | 3.23 | 188.07 | 6.72 | N/A | 新冠肺炎疫苗自110年8月開始銷售 | ||
| 2022/1 | 2.76 | -20.88 | 372.35 | 2.76 | 372.35 | 18.23 | N/A | 新冠肺炎疫苗自110年8月開始銷售 | ||
| 2021/12 | 3.49 | -70.82 | 360.82 | 39.22 | 537.13 | 21.76 | N/A | 新冠肺炎疫苗自110年8月開始持續銷售 | ||
| 2021/11 | 11.97 | 90.31 | 1928.72 | 35.73 | 561.89 | 24.11 | N/A | 新冠肺炎疫苗自110年8月開始持續銷售 | ||
| 2021/10 | 6.29 | 7.57 | 1037.37 | 23.75 | 394.09 | 19.81 | N/A | 新冠肺炎疫苗自110年8月開始持續銷售 | ||
| 2021/9 | 5.85 | -23.78 | 838.72 | 17.46 | 310.45 | 13.86 | N/A | 新冠肺炎疫苗自110年8月開始持續銷售 | ||
| 2021/8 | 7.67 | 2187.12 | 1717.83 | 11.61 | 219.83 | 8.55 | N/A | 主要係因新冠肺炎疫苗開始銷售所致 | ||
| 2021/7 | 0.34 | -37.85 | -32.28 | 3.94 | 22.79 | 1.44 | N/A | - | ||
| 2021/6 | 0.54 | -4.81 | 6.21 | 3.61 | 32.7 | 0.0 | N/A | - | ||
| 2021/5 | 0.57 | -11.62 | 83.08 | 3.07 | 38.8 | 0.0 | N/A | 主要係藥品代工收入增加所致。 |
| 年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 | 年/月 | 營收 |
|---|---|---|---|---|---|---|---|---|---|
| 2026/1 | 0.93 | 2025/1 | 0.97 | 2024/1 | 0.78 | 2023/1 | 0.6 | 2022/1 | 2.76 |
| 2026/2 | 0.68 | 2025/2 | 0.89 | 2024/2 | 0.7 | 2023/2 | 0.51 | 2022/2 | 0.47 |
| 2026/3 | 1.0 | 2025/3 | 3.13 | 2024/3 | 1.03 | 2023/3 | 0.54 | 2022/3 | 1.62 |
| 2026/4 | 0.94 | 2025/4 | 1.05 | 2024/4 | 1.01 | 2023/4 | 0.53 | 2022/4 | 0.54 |
| N/A | N/A | 2025/5 | 1.19 | 2024/5 | 1.42 | 2023/5 | 0.74 | 2022/5 | 0.62 |
| N/A | N/A | 2025/6 | 1.36 | 2024/6 | 1.11 | 2023/6 | 0.78 | 2022/6 | 0.8 |
| N/A | N/A | 2025/7 | 1.15 | 2024/7 | 1.24 | 2023/7 | 0.71 | 2022/7 | 0.54 |
| N/A | N/A | 2025/8 | 1.11 | 2024/8 | 1.14 | 2023/8 | 1.66 | 2022/8 | 0.5 |
| N/A | N/A | 2025/9 | 1.71 | 2024/9 | 1.99 | 2023/9 | 1.8 | 2022/9 | 0.67 |
| N/A | N/A | 2025/10 | 1.42 | 2024/10 | 1.16 | 2023/10 | 1.56 | 2022/10 | 0.66 |
| N/A | N/A | 2025/11 | 0.9 | 2024/11 | 1.09 | 2023/11 | 1.27 | 2022/11 | 0.72 |
| N/A | N/A | 2025/12 | 0.95 | 2024/12 | 1.06 | 2023/12 | 0.86 | 2022/12 | 0.65 |
- 每季的合約負債通常會反應在未來半年到一年後的營收
| 合約負債 QoQ YoY | |||
|---|---|---|---|
| 26Q1 (8) | 1.56 | -3.11 | 4.0 |
| 25Q4 (7) | 1.61 | 3.21 | -30.3 |
| 25Q3 (6) | 1.56 | -2.5 | -32.17 |
| 25Q2 (5) | 1.6 | 6.67 | -29.2 |
| 25Q1 (4) | 1.5 | -35.06 | 0.0 |
| 24Q4 (3) | 2.31 | 0.43 | 0.0 |
| 24Q3 (2) | 2.3 | 1.77 | 0.0 |
| 24Q2 (1) | 2.26 | 0.0 | 0.0 |